News
News
Explore recent news, events, and media resources
Explore recent news, events, and
media resources
Read More ➤
Read More ➤
November 7, 2025
Sound Biologics Announces FDA Clearance of IND Application for QLP3119
November 7, 2025
Sound Biologics Announces FDA Clearance of IND Application for QLP3119
Read More ➤
Read More ➤
October 16, 2024
Sound Biologics Announces Breakthrough Approval of PSB205 by the NMPA
PSB205/QL1706, a bifunctional anti-PD-1 and anti-CTLA-4 MabPair product, gained accelerated approval by the National Medical Products Administration (NMPA) in China.
October 16, 2024
Sound Biologics Announces Breakthrough Approval of PSB205 by the NMPA
PSB205/QL1706, a bifunctional anti-PD-1 and anti-CTLA-4 MabPair product, gained accelerated approval by the National Medical Products Administration (NMPA) in China.
Read More ➤
Read More ➤
June 3, 2022
Sound Biologics Announces Presentations at ASCO 2022 Annual Meeting
PSB205/QL1706, a bifunctional anti-PD-1 and anti-CTLA-4 MabPair product, demonstrates anti-tumor effects with acceptable tolerability and manageable toxicity.
June 3, 2022
Sound Biologics Announces Presentations at ASCO 2022 Annual Meeting
PSB205/QL1706, a bifunctional anti-PD-1 and anti-CTLA-4 MabPair product, demonstrates anti-tumor effects with acceptable tolerability and manageable toxicity.
Read More ➤
Read More ➤
April 13, 2021
Sound Biologics Announces Proof-of-Concept Success at AARC Annual Meeting
Phase 1 Study results for PSB205, a bifunctional anti-PD-1 and anti-CTLA-4 MabPair product, provides proof-of-concept and early clinical validation of the MabPair platform.
April 13, 2021
Sound Biologics Announces Proof-of-Concept Success at AARC Annual Meeting
Phase 1 Study results for PSB205, a bifunctional anti-PD-1 and anti-CTLA-4 MabPair product, provides proof-of-concept and early clinical validation of the MabPair platform.
Read More ➤
Read More ➤
April 10, 2019
Sound Biologics Announces FDA Allowance of its IND Application for PSB205, an Anti-PD-1/CTLA-4 MabPair, in Relapsed and Refractory Solid Tumors
April 10, 2019
Sound Biologics Announces FDA Allowance of its IND Application for PSB205, an Anti-PD-1/CTLA-4 MabPair, in Relapsed and Refractory Solid Tumors
